Chemotherapy for Triple-Negative Breast Cancer: Is More Better?

Affiliations

¹ Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Harvard Medical School, Boston, MA.
² Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Harvard Medical School, Boston, MA hburstein@partners.org.

Editorial

Erica L Mayer et al. J Clin Oncol. 2016.

. 2016 Oct 1;34(28):3369-71.

doi: 10.1200/JCO.2016.68.4068. Epub 2016 Aug 22.

¹ Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Harvard Medical School, Boston, MA.
² Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Harvard Medical School, Boston, MA hburstein@partners.org.

No abstract available

Comment on

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.
Colleoni M, Gray KP, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A. Colleoni M, et al. J Clin Oncol. 2016 Oct 1;34(28):3400-8. doi: 10.1200/JCO.2015.65.6595. Epub 2016 Jun 20. J Clin Oncol. 2016. PMID: 27325862 Free PMC article. Clinical Trial.